Purpose: To investigate the clinical relevance of the recently characterized human
oncoprotein cancerous inhibitor of protein phosphatase 2A (CIP2A) in human breast cancer. …

Senescence induction contributes to cancer therapy responses and is crucial for p53-mediated
tumor suppression. However, whether p53 inactivation actively suppresses senescence …

Induction of terminal proliferation arrest, senescence, is important for in vivo tumor-suppressive
function of p53. Moreover, p53-mutant cells are highly resistant to senescence induction …

These results identify CIP2A as a nongenetic driver and therapeutic target in basal-like breast
cancer that regulates DNA damage–induced G 2 –M checkpoint and proliferative signaling…

An understanding of the mechanisms determining MYC's transcriptional and proliferation-promoting
activities in vivo could facilitate approaches for MYC targeting. However, post-…

Neuroblastoma is a neural crest-derived childhood tumor of the peripheral nervous system
in which MycN amplification is a hallmark of poor prognosis. Here we show that MycN is …

Checkpoint kinase Chk1 is constitutively active in many cancer cell types and new generation
Chk1 inhibitors show marked antitumor activity as single agents. Here we present a …

Systemic understanding of protein phosphatase 2A (PP2A)-regulated cellular processes is
still at infancy. Here, we present mass-spectrometry analysis of phospho-targets (…

Despite saturated genetic profiling of breast cancers, oncogenic drivers for the clinically
challenging basal-like breast cancer (BLBC) subtype are still poorly understood. Here, we …

The Department of Pathology, University of Turku, Turku Centre for Biotechnology,
University of Turku and Åbo Akademi University and Turku Doctoral Programme of …